Use of anti-pd-l1/cd47 bispecific antibody in treatment of diseases
AssigneeBio-Thera Solutions, Ltd.
InventorsYifan Chen, Ziyi Fu, Qiulian Liang, Jin-Chen Yu, Shengfeng Li
Life of this patent
Estimating the term…
Abstract
The present invention discloses use of an anti-PD-L1/CD47 bispecific antibody in the treatment of a disease. A treatment method comprises administering to a patient in need thereof an effective amount of an anti-PD-L1/CD47 bispecific antibody or an antigen-binding fragment.
Claims41
A method for treating an autoimmune disease, an inflammatory disease, an infectious disease, or a tumor, comprising administering to a patient in need thereof an effective amount of an anti-PD-L1/CD47 bispecific antibody or an antigen-binding fragment;
- wherein
- the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment is administered once every two days to once every six weeks, at a dose of 0.1 mg/kg to 100 mg/kg or at a dose of 6 mg to 3000 mg;
- the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment comprises a variable region a specifically binding to PD-L1 and a variable region b specifically binding to CD47;
- wherein the variable region a comprises at least one or more of VHa CDR1 set forth in SEQ ID NO:
- 1, VHa CDR2 set forth in SEQ ID NO:
- 2, VHa CDR3 set forth in SEQ ID NO:
- 3, VLa CDR1 set forth in SEQ ID NO:
- 4, VLa CDR2 set forth in SEQ ID NO:
- 5, and VLa CDR3 set forth in SEQ ID NO:
- 6;
- the variable region b comprises at least one or more of VHb CDR1 set forth in SEQ ID NO:
- 7, VHb CDR2 set forth in SEQ ID NO:
- 8, VHb CDR3 set forth in SEQ ID NO:
- 9, VLb CDR1 set forth in SEQ ID NO:
- 4, VLb CDR2 set forth in SEQ ID NO:
- 5, and VLb CDR3 set forth in SEQ ID NO:
- 6.
Use of an anti-PD-L1/CD47 bispecific antibody or an antigen-binding fragment in the treatment of an autoimmune disease, an inflammatory disease, an infectious disease, or a tumor;
- wherein the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment is administered in an amount of 0.1 mg/kg to 100 mg/kg once every two days to once every six weeks;
- the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment comprises a variable region a specifically binding to PD-L1 and a variable region b specifically binding to CD47;
- wherein the variable region a comprises at least one or more of VHa CDR1 set forth in SEQ ID NO:
- 1, VHa CDR2 set forth in SEQ ID NO:
- 2, VHa CDR3 set forth in SEQ ID NO:
- 3, VLa CDR1 set forth in SEQ ID NO:
- 4, VLa CDR2 set forth in SEQ ID NO:
- 5, and VLa CDR3 set forth in SEQ ID NO:
- 6;
- the variable region b comprises at least one or more of VHb CDR1 set forth in SEQ ID NO:
- 7, VHb CDR2 set forth in SEQ ID NO:
- 8, VHb CDR3 set forth in SEQ ID NO:
- 9, VLb CDR1 set forth in SEQ ID NO:
- 4, VLb CDR2 set forth in SEQ ID NO:
- 5, and VLb CDR3 set forth in SEQ ID NO:
- 6.
Use of an anti-PD-L1/CD47 bispecific antibody or an antigen-binding fragment in the preparation of a medicament for treating an autoimmune disease, an inflammatory disease, an infectious disease, or a tumor;
- wherein the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment is administered in an amount of 0.1 mg/kg to 100 mg/kg once every two days to once every six weeks;
- the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment comprises a variable region a specifically binding to PD-L1 and a variable region b specifically binding to CD47;
- wherein the variable region a comprises at least one or more of VHa CDR1 set forth in SEQ ID NO:
- 1, VHa CDR2 set forth in SEQ ID NO:
- 2, VHa CDR3 set forth in SEQ ID NO:
- 3, VLa CDR1 set forth in SEQ ID NO:
- 4, VLa CDR2 set forth in SEQ ID NO:
- 5, and VLa CDR3 set forth in SEQ ID NO:
- 6;
- the variable region b comprises at least one or more of VHb CDR1 set forth in SEQ ID NO:
- 7, VHb CDR2 set forth in SEQ ID NO:
- 8, VHb CDR3 set forth in SEQ ID NO:
- 9, VLb CDR1 set forth in SEQ ID NO:
- 4, VLb CDR2 set forth in SEQ ID NO:
- 5, and VLb CDR3 set forth in SEQ ID NO:
- 6.
A kit comprising an anti-PD-L1/CD47 bispecific antibody or an antigen-binding fragment and instructions for directing administration of the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment at 0.1 mg/kg to 100 mg/kg to a patient in need thereof once every two days to once every six weeks;
- wherein
- the anti-PD-L1/CD47 bispecific antibody or the antigen-binding fragment comprises a variable region a specifically binding to PD-L1 and a variable region b specifically binding to CD47;
- wherein the variable region a comprises at least one or more of VHa CDR1 set forth in SEQ ID NO:
- 1, VHa CDR2 set forth in SEQ ID NO:
- 2, VHa CDR3 set forth in SEQ ID NO:
- 3, VLa CDR1 set forth in SEQ ID NO:
- 4, VLa CDR2 set forth in SEQ ID NO:
- 5, and VLa CDR3 set forth in SEQ ID NO:
- 6;
- the variable region b comprises at least one or more of VHb CDR1 set forth in SEQ ID NO:
- 7, VHb CDR2 set forth in SEQ ID NO:
- 8, VHb CDR3 set forth in SEQ ID NO:
- 9, VLb CDR1 set forth in SEQ ID NO:
- 4, VLb CDR2 set forth in SEQ ID NO:
- 5, and VLb CDR3 set forth in SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.